See More Hear More Watch More Hear More Get on iTunes
WSJ Daily Minute WSJMinute

Valeant Pharmaceuticals Boosts Bid

A new bid by Valeant Pharmaceuticals could value Allergan at more than $56 billion. Together with investor William Ackman, Valeant is boosting their offer by $15 a share to keep them from striking a rival deal. If completed, that would make it the largest deal of the year.


More from